Novartis’ Kisqali bests AZ’ Faslodex in breast cancer trial
Adding Kisquali to Faslodex resulted in an almost 30% reduction in risk of death compared to Faslodex alone
Read More
Tag: fulvestrant
NICE U-turn for Kisqali in breast cancer
NICE has recommended Novartis’ Kisqali just three months after its initial rejection.
Read More
NICE nod for breast cancer delay drug
Eli Lilly’s Verzenio has been recommended for use within the Cancer Drugs Fund by NICE.
Read More
Breast cancer patients barred from NHS access to Faslodex
The National Institute for Health and Care has issued final guidelines rejecting AstraZeneca’s Faslodex for certain patients with breast cancer.
Read More
EU, US approvals for Faslodex combinations
AstraZeneca’s Faslodex has been cleared on both sides of the Atlantic for use in combination with a CDK4/6 inhibitor.
Read More
Ten new medicines leap towards EU approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis and eosinophilic asthma.
Read More
NICE turns down AZ’ Faslodex for breast cancer
It is looking unlikely that AstraZeneca’s breast cancer drug Faslodex will be routinely funded on the NHS to delay growth of a specific type of breast cancer, after cost regulators concluded that its benefit over existing therapies has not been shown at this time.
Read More
EU OKs first-line use of AZ’ Faslodex
EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.
Read More
Priority review for Lilly’s breast cancer drug
Eli Lilly’s experimental breast cancer drug abemaciclib has been granted a priority review by US regulators for two indications, and is now on track to be filed in Europe later this year.
Read More
Come-back for Lilly’s breast cancer drug
An experimental breast cancer combination being developed by Eli Lilly has hit its key goal of extending progression-free survival (PFS) in certain patients with advanced disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
